Main Newsletter
Mastery Series
Therapy Series
Letter From The Editor

It is time to get out your wallets and take out the big bills that you have hiding in the back. Why do you need to do this? Because the cost of poor diabetes care is growing larger every day. For years we have known that patients with diabetes cost more to take care of than those without, and in the past three years we have added 3 million newly diagnosed to the 26 million we already had. Because these patients are being diagnosed at a younger age, they will have more time for the complications to develop. Find out why your wallet will soon be empty here. This becomes even more of a crisis when you add in the fact that dementia patients have an increased risk of diabetes.

One of the ways we can overcome this surge is to be more aggressive in our first therapy choices, and starting with a triple drug therapy may be the answer.


Announcements: Sunday, March 29, 7PM ET

From "An Olympic legend shares his troubles with and inspiring triumphs over diabetes. Plus, a low carb Asian appetizer in the dLife kitchen, and a profile of MLB pro pitcher Brandon Morrow." Sundays live online at at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at

TCOYD Health Fair Conference, Austin Convention Center, Austin, Texas, Saturday, March 28, 2015

With a day packed full of education, motivational tools, one-on-one sessions, and workshops, the TCOYD health fair is a great way to get your patients to take better care of their health and themselves.

We can make a difference!


Dave Joffe, Editor-in-chief

 … Read More

Scroll down for items in the current newsletter

Tool for your Practice


The Centers for Disease Control and Prevention (CDC) and the American Medical Association (AMA) have created a toolkit that health care teams can use as a guide to Screen, Test and Act Today (STAT) by referring patients to in-person or online diabetes prevention programs. You can download a complete toolkit at the Prevent Diabetes STAT website. The kit includes: a brief overview of the evidence-based diabetes prevention program and a rationale for engaging with the program; short summaries of studies conducted over the last 15 years, creating the evidence base for the prevention of diabetes through lifestyle change interventions; a questionnaire for patients to learn about their risk for prediabetes while helping care teams identify patients at great risk; and a patient handout for use in waiting areas to increase awareness and pave the way for conversations about screening, testing and referral. The kit also assists clinicians in advocating to their colleagues about the value of incorporating diabetes prevention screening and referral into their practices. Prevent Diabetes STAT


Product of the Week


FDA Approves Aflibercept for Diabetic Retinopathy in Patients with Diabetic Macular Oedema. The US Food and Drug Administration (FDA) expanded the approved use for aflibercept (Eylea) injection to treat diabetic retinopathy in patients with diabetic macular oedema (DME). Aflibercept is administered by a physician as an injection into the eye once a month for the first 5 injections and then once every 2 months. It is intended to be used along with appropriate interventions to control blood sugar, blood pressure, and cholesterol. The safety and efficacy of aflibercept to treat diabetic retinopathy in patients with DME were evaluated in 679 participants in 2 clinical studies where participants were randomised to receive aflibercept or macular laser photocoagulation. At week 100, participants being treated with aflibercept showed significant improvement in the severity of their diabetic retinopathy, compared with patients who did not receive aflibercept.


Mobile App of the Week

ASCVD Risk Estimator

The ASCVD Risk Estimator is published jointly by the American College of Cardiology (ACC) and the American Heart Association (AHA) to help health care providers and patients estimate 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD) using the Pooled Cohort Equations and lifetime risk prediction tools. This app is intended as a companion tool to the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk and the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. The ASCVD Risk Estimator provides easy access to recommendations specific to the risk estimates produced by the calculator. Additionally, the app includes readily accessible guideline reference information for both providers and patients related to therapy, monitoring, and lifestyle. For more information and to download the app.


Test Your Knowledge Question #774


The American Diabetes Association recommends many non-pregnant adults with type 2 diabetes work to achieve an A1C = 7%. Which one of the following glycemic patterns would support this goal?

a. Fasting glucose <70, postprandial glucose<140, mean plasma glucose<120-140

b. Fasting glucose <126, postprandial glucose<200, mean plasma glucose<180

c. Fasting glucose <130, postprandial glucose<180, mean plasma glucose<150 -160

d. Fasting glucose <130, postprandial glucose<200, mean plasma glucose<150 -160

For the complete question and answer, just follow this link. 


Diabetes In Control Has Over 15500 Studies & Articles In Our Archives

Quote of the Week!

"The greater part of our happiness or misery depends upon our dispositions, and not upon our circumstances."
         ...Martha Washington

Diabetes in Control gratefully acknowledges the assistance of the following  pharmacy doctoral candidates in the preparation of this week's newsletter: 

Ryan Balestreri, LECOM College of Pharmacy

Trisha Le, LECOM College of Pharmacy


Cast Your Vote
Are you interested in learning how to improve patient care by doing a reimbursable comprehensive diabetic foot exam?
CME/CE of the Week
Lois Jovanovic, MD

Category: General Diabetes
Credits: .75


Search Articles On Diabetes In Control